Six must-dos to avoid bacterial apocalypse
This article was originally published in Scrip
Before the advent of antibiotics infectious diseases accounted for 45% of all deaths. While that mortality rate has fallen to 7% in the developed economies the emergence of antimicrobial resistant pathogens means there is a danger of returning to a pre-antibiotic world. This was the stark warning from Professor Dame Sally Davies, the chief medical officer of England, in her keynote speech at the opening of BioInfect 2013, organized by Bionow, BioHub and Redx Pharma at AstraZeneca's Alderley Park facility in the UK on 26 November.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.